Brandon Capital Partners
Est. dry powder
$127.8M
Raised, not yet invested
AUM
$574.2M
Assets under management
Latest fund
$170M
MRCF BTF
Est. cheque size
$288.5K–
From fund sizes
Deals, last 12 months
3
Last seen investing Jun 2026
About Brandon Capital Partners
Brandon Capital is Australasia based leading life science venture capital firm, with a global presence supported by key partnerships and team members across the US and UK. From early-stage seed investment to expansion capital, and Brandon Capital supports life science companies from proof-of-concept to commercialisation. Managed by Brandon Capital, Brandon BioCatalyst (formerly the Medical Research Commercialisation Fund) is an ANZ collaboration of over 50 leading medical research institutes, investors, and government united to progress the next generation of medical therapies and technology for health improvements and life-saving.
- Type
- Venture Capital Firm
- Headquarters
- Melbourne, Victoria, Australia
- Stages
- SeedSeries ASeries BSeries CSeries DEarly Stage
- Est. cheque size
- $288.5K–$8.6M
- Sectors
- Healthcare
- Regions
- Australasia
- Strategies
- Pre-Seed, Seed, Series A
Where they invest
From deals and portfolio companies on record
Most frequent rounds
- Series A25
- Series B14
- Seed8
- Series C5
- Series D4
Across 70 deals
Portfolio sectors
- Biotechnology19
- Pharmaceuticals13
- Medical Devices & Equipment8
- Healthcare Specialists2
Across 42 companies
Portfolio countries
- Australia24
- US8
- UK5
- New Zealand2
- Germany1
Across 42 companies
Recent investments
Newest 5 of 70
- Series D$218.3M
Advancell Pty Ltd
Jun 2026 · Series D
- Series B$2.1M
Lumonus Pty Ltd
Mar 2026 · Series B
- Unspecified Round$18.7M
OncoRes Medical Pty Ltd
Feb 2026 · Unspecified Round
- Series B$22M
Ena Respiratory Pty Ltd
Oct 2025 · Series B
- Series B$67.2M
NRG Therapeutics Ltd
Sep 2025 · Series B
Offices
4 locations
- Melbourne, Victoria, AustraliaHQ
- San Francisco, California, US
- Sydney, New South Wales, Australia
- London, England, UK